Profiel
Kenneth Gruber has held the title of Chief Scientific Officer at Endevica Bio since 2009, which is the year he founded the company.
Actieve functies van Kenneth Gruber
| Bedrijven | Functie | Begin |
|---|---|---|
Endevica Bio
 Endevica Bio BiotechnologyHealth Technology Endevica Bio is a biotechnology company that creates first-in-class peptide drug candidates to treat cachexia caused by diseases like cancer, renal failure, and congestive heart failure. The company is based in Columbia, MO. The company's technology platform, protected by a family of patents and pending applications, allows for the modification of peptides to modulate activity of G-protein coupled receptors behind the blood-brain barrier. Endevica Bio's synthetic peptides are stable in plasma and have drug-like characteristics. The company was founded in 2009 by Dr. Kenneth Gruber, who wanted to create synthetic peptides that would show drug-like characteristics. Russ Potterfield has been the CEO of the company since 2020. | Oprichter | 01-01-2009 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Endevica Bio
Endevica Bio BiotechnologyHealth Technology Endevica Bio is a biotechnology company that creates first-in-class peptide drug candidates to treat cachexia caused by diseases like cancer, renal failure, and congestive heart failure. The company is based in Columbia, MO. The company's technology platform, protected by a family of patents and pending applications, allows for the modification of peptides to modulate activity of G-protein coupled receptors behind the blood-brain barrier. Endevica Bio's synthetic peptides are stable in plasma and have drug-like characteristics. The company was founded in 2009 by Dr. Kenneth Gruber, who wanted to create synthetic peptides that would show drug-like characteristics. Russ Potterfield has been the CEO of the company since 2020. | Health Technology |
